{
    "url_original": "https://www.wsj.com/articles/pfizer-vaccine-executive-moves-to-rival-glaxosmithkline-11638277315?mod=business_lead_pos2",
    "url": "pfizer-vaccine-executive-moves-to-rival-glaxosmithkline-11638277315",
    "title": "Pfizer Vaccine Executive Moves to Rival GlaxoSmithKline",
    "sub_head": "GSK, a vaccine leader, lagged behind rivals in the race to develop a Covid-19 shot",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-443072?width=860&height=573",
    "image_1": "im-443072.jpg",
    "time": "2021-11-30 08:17:00",
    "body": "Pfizer Inc.’s  top viral vaccine-science executive is leaving the pharmaceutical giant for rival  GlaxoSmithKline  PLC, a high-profile industry move that comes as Pfizer and other vaccine makers scramble to assess how their shots will stand up to a new variant of the coronavirus that causes Covid-19.<br />GSK said Philip Dormitzer, previously Pfizer’s chief scientific officer for viral vaccines, will join the British drug giant as its global head of vaccines research and development. His first day will be Friday, the company said."
}